Click Here to View the Activity
This educational activity is specifically designed for hematologists, internists, oncologists, and other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) interested in and/or involved in the care of patients with chronic lymphocytic leukemia (CLL).
This stimulating Webcast is taken directly from the symposium held at the American Society of Hematology annual meeting on December 7, 2007 and is titled “ Great Debates in CLL: Facing Today’s Controversies and Tomorrow’s Challenges.” Dr Susan O’ Brien chaired the innovative symposium that included debates and didactic presentations focused on issues in CLL, such as first-line therapy, relapsed/refractory disease, treatment of minimal residual disease, and novel emerging therapies.
Upon completion of this educational activity, attendees should be able to:
- State the rationale for treating or not treating patients with CLL
- Describe and discuss the value of molecular and biologic markers in determining prognosis and planning treatment for patients with CLL
- Compare and contrast the various therapeutic regimens used as first-line treatments for CLL
- Explain the different treatment options for managing minimal residual CLL disease
- Design appropriate therapeutic plan(s) for the effective management of relapsed and refractory disease in CLL
- Discuss the recent clinical trials looking at new treatment modalities for CLL and explain how these modalities will be applied in the future
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options including but not limited to the use of generic names to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
| John Byrd, MD |
Biogen Idec Inc1, Geron Corporation1, Novartis Pharmaceuticals Corporation1, Pharmion Corporation4 |
| Martin Dyer, MD |
Berlex Laboratories, Inc./Schering-Plough Corporation2 |
| Alessandra Ferrajoli, MD |
Celgene Corporation1,2, Berlex Laboratories, Inc.1 |
| Susan O’Brien, MD |
Berlex Laboratories, Inc.1, Biogen Idec Inc.1, Genentech BioOncology1 |
| Stephan Stilgenbauer, MD |
Amgen Inc.1,2; Ribosepharm1,2; Roche Laboratories, Inc.1,2; Santaris Pharma A/S1,2; Schering-Plough Corporation1,2 |
| Mark A. Weiss, MD |
Berlex Laboratories, Inc.1; Hospira1; Biogen Idec Inc1; Genentech BioOncology1 |
The following speakers have reported an affiliation with the supporters of this conference:
| Stephan Stilgenbauer, MD |
Bayer HealthCare Corporation1,2 |
All materials are included with the permission of the authors.
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Kenneth Richardson, MD, Bradley Bongiovanni, ND, and Becky Lynch, RN, own stock options for AmerisourceBergen.
This activity is sponsored by Imedex, LLC.
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com
This Webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this Webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex or the American School of Oncology.
The following company has provided an unrestricted educational grant in support of this activity: Bayer HealthCare Corporation.
Click Here to View the Activity |
